Ionis Pharmaceuticals Inc
IONS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.23B
Close$
$-57.64
243.6% downside
Current Fair Value
243.6% downsideOvervalued by 243.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.23 Billion |
|---|---|
| Enterprise Value | $7.60 Billion |
| Earnings per Share | $-2.38 |
| Beta | 0.38 |
| Outstanding Shares | 165,419,000 |
Return
| Return on Equity | -48.16% |
|---|---|
| Return on Assets | -7.07% |
| Return on Invested Capital | -7.85% |
Valuation & Multiples
| P/E Ratio | -12.58 |
|---|---|
| PEG | 6.54 |
| Price to Sales | 6.69 |
| Price to Book Ratio | 20.08 |
| Enterprise Value to Revenue | 6.77 |
| Enterprise Value to EBIT | -36.12 |
| Enterprise Value to Net Income | -36 |
| Total Debt to Enterprise | 0.32 |
| Debt to Equity | 5.51 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$-1.22
Consensus analyst estimateRevenue Estimate
$181.56 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 60.87% |
|---|---|
| Total Calls | 1,754▼ 99.96% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.12%▼ 108.52% |
|---|---|
| Total Invested | $82.79M▼ 99.42% |
| Investors Holding | 112▼ 447.00% |
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...